Michael Joseph Driscoll Sells 25,000 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO) Director Michael Joseph Driscoll sold 25,000 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total value of $127,500.00. Following the sale, the director now directly owns 166,879 shares in the company, valued at approximately $851,082.90. The trade was a 13.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Organogenesis Stock Down 8.5 %

ORGO stock opened at $5.16 on Friday. Organogenesis Holdings Inc. has a one year low of $2.17 and a one year high of $6.71. The stock has a market capitalization of $654.43 million, a P/E ratio of -86.00 and a beta of 1.66. The company has a 50 day moving average price of $3.65 and a two-hundred day moving average price of $3.35. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09.

Analyst Ratings Changes

Separately, Morgan Stanley upped their target price on shares of Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a report on Wednesday.

Hedge Funds Weigh In On Organogenesis

Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in Organogenesis in the 4th quarter valued at about $38,000. Captrust Financial Advisors acquired a new stake in shares of Organogenesis in the third quarter worth approximately $36,000. Intech Investment Management LLC purchased a new stake in Organogenesis in the third quarter valued at approximately $43,000. Palumbo Wealth Management LLC acquired a new position in Organogenesis during the fourth quarter worth approximately $65,000. Finally, ProShare Advisors LLC raised its stake in Organogenesis by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 20,329 shares of the company’s stock worth $65,000 after purchasing an additional 6,689 shares during the period. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.